In my recent Carried Interest Is A Hidden Gem post, I include an excerpt from Bruce Flatt's (CEO of Brookfield Corporation) February 13, 2025 Letter To Shareholders in which he explains Carried Interest and why it is a hidden gem. Coincidentally, on February 14 2025, BlackRock (BLK) communicated its Board's decision (see Form 8-K) to [...]
Rollins (ROL) intends to double its revenue over the coming decade. This will require access to the capital markets. This now becomes possible with the assignment of investment-grade corporate credit ratings from Fitch and S&P Global. I last reviewed Rollins (ROL) in this April 30, 2024 post at which time the most current financial information [...]
In 2020, Becton Dickinson (BDX) embarked on its 5-year BD2025 strategy. Although BDX's total investment return over the past ~8 - ~9 years is disappointing, its transition into a pure-play medtech company is approaching an end. I am, therefore, sticking with this investment since I think future performance will be superior to that of [...]
I last reviewed Blackstone (BX) in this post following the release of Q3 and YTD2024 results. Now that we have BX's Q4 and FY2024 results, I revisit this existing holding. Coincidentally, the account in which I hold BX shares unexpectedly reported multiple entries with a February 5, 2025 trade date but back dated settlement dates. [...]
With all the changes brought on by artificial intelligence, I have no idea which companies are likely to be long-term winners. Microsoft (MSFT) has a proven track record to navigate the tech sector safely. As a result, it suits my relatively conservative investor profile. Despite not having written about MSFT since my November 11, 2021 [...]
Buy undervalued Danaher (DHR) shares amid market challenges. In my December 8, 2024 Danaher (DHR) post, I disclose the purchase of an additional 100 shares in a 'Core' account in the FFJ Portfolio. My ~$233.97 purchase price was just a shade above the ~$229 price I paid to acquire 100 additional shares on November 18. [...]
On January 27, Lockheed Martin's (LMT) shares closed at ~$503.70. Following the release of Q4 and FY2024 results and FY2025 outlook on January 28, 2025, the share price plunged ~$46. I now view Lockheed Martin's share price weakness as a buying opportunity and acquired an additional 50 shares @ $457.75 in one of the 'Core' [...]
After ~38 years of investing, I have lost count of my errors of omission and commission. Intuitive Surgical (ISRG) has to rank amongst one of my biggest errors! On October 20, 2021, I initiated a 30 share position in one of the 'Core' accounts within the FFJ Portfolio. I subsequently acquired another 30 shares on [...]
High entry barriers fortify Union Pacific (UNP). My UNP exposure, however, is minimal with my only purchase being 200 shares @ $142.17 on March 9, 2020 while I was on a ski vacation in British Columbia; we were days from experiencing a 'shut down' of the North American economy because of the COVID pandemic. My [...]
Johnson & Johnson (JNJ) is virtually irrelevant to my investment strategy, and therefore, I rarely look at this investment. With the release of the Q4 and FY2024 financial results on January 22, 2025, I figure this is the opportunity to look at it more closely. Twice a year I disclose which companies are my [...]